After the last pump and dump of IGC caused by Cohort 2 of IGC`s Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients
now India Globalization Capital comes with another bullish news on the subject: the cannabis-based investigational drug IGC-AD1 was safe and well-tolerated by the Alzheimer’s trial participants!
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.